About Novadip
Novadip is a company based in Mont-saint-guibert (Belgium) founded in 2013. Novadip has raised $77.04 million across 5 funding rounds from investors including European Investment Bank, New Science Ventures and Fund+. The company has 39 employees as of December 31, 2021. Novadip offers products and services including NVD-003 and NVD-X3. Novadip operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Mont-saint-guibert, Belgium
- Employees 39 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Novadip Biosciences
-
Annual Revenue
Not available
-
Net Profit
-$1.64 K (USD)-8as on Dec 31, 2021
-
EBITDA
-$1.65 K (USD)-7as on Dec 31, 2021
-
Total Equity Funding
$77.04 M (USD)
in 5 rounds
-
Latest Funding Round
$19.69 M (USD), Debt – Venture
Dec 15, 2023
-
Investors
European Investment Bank
& 13 more
-
Employee Count
39
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Novadip
Novadip offers a comprehensive portfolio of products and services, including NVD-003 and NVD-X3.
Product for accelerating healing of large bone defects.
Therapy for bone non-union and spine fusion treatments.
People of Novadip
Unlock access to complete
Funding Insights of Novadip
Novadip has successfully raised a total of $77.04M across 5 strategic funding rounds. The most recent funding activity was a Debt – Venture round of $19.69 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Novadip
Novadip has secured backing from 14 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include European Investment Bank, New Science Ventures and Fund+.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finance and advisory services for infrastructure projects are provided.
|
Locked | Locked | Locked | |
|
Early, mid, and late-stage investments are made in science sectors.
|
Locked | Locked | Locked | |
|
Fund+ is focused on investing in life sciences companies.
|
Locked | Locked | Locked |
Investor details for Novadip
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Novadip
Investment portfolio details for Novadip
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Novadip
Detailed financials for Novadip
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Novadip Comparisons
Peer comparison for Novadip
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Novadip
Novadip operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Novadip
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Novadip
Complete news archive for Novadip
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novadip
Novadip was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Novadip is headquartered in Mont-saint-guibert, Belgium.
Novadip is a funded company, having raised a total of $77.04M across 5 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Novadip is 39.
Novadip was founded in 2013 and is based in Mont Saint Guibert, Belgium. Operations focus on the biotechnology sector, where stem cell-based regenerative therapeutics are developed for bone healing disorders and defects. Key products include NVD-X3 for hard tissue reconstruction and NVD-X2 for soft tissue reconstruction. The m3 platform, known as creost, utilizes autologous adipose-derived stem cells to form 3D osteogenic structures, enabling reconstruction of critical-size bone defects without scaffolds.
Novadip's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Novadip offers NVD-003 and NVD-X3.
Novadip has 14 investors. Key investors include European Investment Bank, New Science Ventures, Fund+, CR-CP Life Sciences Fund, and Vives Fund.